Abstract
Introduction: Amniotic fluid obtained from first- or second trimester amniocentesis has customarily been used for the cultivation of c-Kit positive amniotic fluid stem cells. These stem cells have been shown to have a vast differentiation potential and, most noteworthy, considerable genomic stability and a lack of teratoma formation upon injection into patients. These characteristics have made amniotic fluid stem cells of immeasurable value for their potential therapeutic use. The advent of various technological advances has, however, obviated the need for amniocentesis, thereby leading to a severe shortage of donor material for therapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
